Yellow Prince
An obscure cannabis strain circulated by a handful of seed vendors, with almost no verifiable lineage or lab data.
Yellow Prince is one of hundreds of cannabis strain names that exists more as a marketing label than a documented cultivar. There is no peer-reviewed literature on it, no widely available chemotype data, and no consensus lineage. If you buy something called Yellow Prince from two different sources, you are almost certainly getting two genetically different plants. Treat everything below — including cultivator claims — as folklore unless you have a lab report for the specific batch in your hand.
Overview
Yellow Prince is a cannabis strain name that appears on a small number of seed bank and dispensary menus but has no significant footprint in peer-reviewed literature, government cultivar databases, or major strain aggregators. Because cannabis strain names are not trademarked in any consistent way and are not tied to genetic verification, different sellers can and do apply the same name to unrelated plants Strong evidence[1][2].
In other words: 'Yellow Prince' is a label, not a guarantee. Two packs of seeds sold under this name from different breeders may share nothing beyond the name on the bag. Everything a vendor tells you about its lineage, chemistry, or effects should be treated as an unverified marketing claim until there is a lab certificate of analysis (COA) for the specific batch.
Chemistry
We could not locate any published cannabinoid or terpene profile for Yellow Prince in peer-reviewed sources, government cultivar registries, or open testing datasets. That means any THC, CBD, or terpene number attached to this name comes from an individual retailer's COA — if it exists at all — and applies only to that one harvest.
More broadly, research shows that strain names are poor predictors of chemical composition. A widely cited 2022 study of nearly 90,000 commercial samples found that flowers sharing the same strain name often had substantially different cannabinoid and terpene profiles, and that the traditional indica/sativa/hybrid labels did not map onto chemistry in a meaningful way Strong evidence[3]. Earlier genetic work reached similar conclusions about mislabeling across the retail market Strong evidence[1].
If you want to know what is actually in a jar of Yellow Prince, the only reliable answer is the COA for that specific batch.
Reported effects
There are no clinical trials on Yellow Prince. There are no controlled human studies on Yellow Prince. Any effect descriptions you see — 'uplifting,' 'creative,' 'euphoric,' 'couch-lock' — come from self-reported user reviews on commercial websites, which are unblinded, subject to expectancy effects, and not tied to verified chemistry Anecdote.
What we can say from broader research: the acute effects of cannabis are driven primarily by total THC dose, route of administration, individual tolerance, set, and setting, with terpenes and minor cannabinoids likely playing a modulating but still poorly quantified role Weak / limited[4]. The popular 'entourage effect' framing is a plausible hypothesis that remains under-tested in humans Disputed[5]. Nothing about the name 'Yellow Prince' tells you how it will feel.
Lineage
We could not find a verifiable, documented lineage for Yellow Prince from a reputable breeder record, seedbank archive, or genetic study No data. Some retail listings speculate about parentage, but these claims are not corroborated across sources and are not backed by genetic testing.
This is common. Cannabis genetics are poorly standardized, and 'lineage' claims in the industry are frequently reconstructed after the fact, borrowed from more famous strains for marketing appeal, or simply guessed. Independent genotyping projects have repeatedly shown that named strains often do not cluster the way their advertised family trees would predict Strong evidence[1][6]. Until someone publishes a marker-based genetic profile of a specific Yellow Prince cut, assume the lineage is unknown.
Cultivation basics
Because there is no consistent genetic reference for Yellow Prince, there are also no reliable, general cultivation parameters. Flowering time, stretch, nutrient tolerance, mold resistance, and yield all depend on the specific phenotype — which in turn depends on which vendor's seeds or clone you got.
If you are growing a plant sold under this name, treat it as an unknown modern hybrid: plan for an 8–10 week flowering window, watch for structure and stretch in the first two weeks of flower, and adjust from there Anecdote. Keep notes. Your grow log is more informative than the strain name.
Marketing vs. reality
The gap between what a strain name promises and what it delivers is the central problem of the retail cannabis market. Yellow Prince is a good example of the low end of that spectrum: a name in circulation, no documented origin, no aggregated chemistry, no clinical data, and no genetic verification.
A few things worth remembering when you encounter any strain in this category:
- Indica vs. sativa labels don't predict effects. This is folklore, not chemistry Strong evidence[3][7].
- Terpene 'dominance' on a menu is only as trustworthy as the lab that tested it, and thresholds like the often-repeated 'myrcene above 0.5% means couch-lock' are marketing folklore with no controlled evidence behind them No data.
- The name on the jar is not the plant. Ask for a COA. If there isn't one, you are buying a story.
None of this makes Yellow Prince bad — it might be a perfectly nice plant. It just means the name alone tells you almost nothing.
Sources
- Peer-reviewed Sawler, J., Stout, J. M., Gardner, K. M., Hudson, D., Vidmar, J., Butler, L., Page, J. E., & Myles, S. (2015). The Genetic Structure of Marijuana and Hemp. PLoS ONE, 10(8), e0133292.
- Peer-reviewed Schwabe, A. L., & McGlaughlin, M. E. (2019). Genetic tools weed out misconceptions of strain reliability in Cannabis sativa: implications for a budding industry. Journal of Cannabis Research, 1(1), 3.
- Peer-reviewed Smith, C. J., Vergara, D., Keegan, B., & Jikomes, N. (2022). The phytochemical diversity of commercial Cannabis in the United States. PLoS ONE, 17(5), e0267498.
- Peer-reviewed MacCallum, C. A., & Russo, E. B. (2018). Practical considerations in medical cannabis administration and dosing. European Journal of Internal Medicine, 49, 12–19.
- Peer-reviewed Russo, E. B. (2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology, 163(7), 1344–1364.
- Peer-reviewed Vergara, D., Baker, H., Clancy, K., Keepers, K. G., Mendieta, J. P., Pauli, C. S., Tittes, S. B., White, K. H., & Kane, N. C. (2016). Genetic and Genomic Tools for Cannabis sativa. Critical Reviews in Plant Sciences, 35(5-6), 364–377.
- Peer-reviewed Piomelli, D., & Russo, E. B. (2016). The Cannabis sativa Versus Cannabis indica Debate: An Interview with Ethan Russo, MD. Cannabis and Cannabinoid Research, 1(1), 44–46.
How this page was made
Generation history
Drafting assistance and fact-check automation are used, with a human operator spot-checking on a weekly basis. See how articles are made.